|
|
Profile
|
Delegates :
Yoshiko "Kumachi" Takaike |
|
Incorporated :
September 4 , 2007 |
Paid in Capital :
62 Million yen |
Employees :
5 人 |
Address :
Nishi-ku Takashima1-1-2 Yokohama-mitsui bil. 15F, Yokohama-si KANAGAWA
〒220-0011
|
TEL/FAX :
+81-45-232-4280 / |
URL：
https://www.deftacapital.jp |
Attachment :
|
Mission/Background :
Our company operates primarily as a venture capital firm, guided by two core principles: “To invest in companies developing innovative technologies essential to humanity and create new industries,” and “To commercialize innovative medicine and realize a society where people remain healthy until the very end of their natural lives.” Founder Hara began launching ventures in the 1980s and later worked as a venture capitalist mainly in the United States. He continues to manage affiliated companies in the U.S. and Hong Kong, offering venture capital and corporate management consulting services.
We manage our funds based on the belief that hands-on support for venture commercialization leads to financial returns. Supporting the commercialization of university technologies is a key pillar of our mission. As a commercialization promotion organization under the GAP Fund, we provide nationwide support to help bring academic innovations to market. |
|
Technology & Business
|
We invest in healthcare sectors including next-generation medical devices, healthcare IoT/ICT, advanced and regenerative medicine, as well as synthetic biology fields such as biotechnology and smart cell technologies—collectively referred to as bio-manufacturing. Our view of healthcare spans prevention, diagnosis, treatment, and prognosis management, and includes foundational technologies like data, materials, and energy. In synthetic biology, we prioritize investment in company clusters capable of forming integrated bio-manufacturing ecosystems, especially those centered around Bacchus Bioinnovation. When supporting university-originated technologies, we focus on social impact and novelty, not limited to biotech or drug discovery, but also embracing broader research with societal relevance.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Management and operation of investment partnership assets, and solicitation/sales of investment partnership interests
|
Discovery
|
Investment in and commercialization support for ventures and startups in the healthcare and synthetic biology fields
|
Early commercialization, overseas expansion
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Through investment in Kobe University spin-off Bacchus Bioinnovation, we are supporting the commercialization of smart cell technology. The company recently succeeded in raising funds through a third-party allotment and has also secured numerous government grants.
PhotoQ3 has achieved stable toxin expression, paving the way for cancer treatment using immunotoxins combined with antibodies. The company plans to commence non-clinical trials targeting brain tumors.
|
|
Alliance strategy
|
Bacchus Bioinnovation is seeking smart cell research and development companies. We welcome proposals for both in-house projects and development projects tailored to specific applications.
PhotoQ3 is seeking partners for collaborative research toward non-clinical trials, as well as technology licensing opportunities.
|
|
|